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The general structure of phthalates, diesters of
phthalic acid, manufactured by reacting
phthalic anhydride with alcohols of desired
carbon-chain length, is shown in Figure 1.
R and R´ are ethyl groups for diethyl phthalate
(DEP) and 2-ethylhexyl groups for di(2-ethyl-
hexyl) phthalate (DEHP). DEP (CAS
no. 84-66-2) is used as a plasticizer for cellu-
lose acetate, as a solvent, and as a carrier for
fragrances in cosmetics and other consumer
products [Agency for Toxic Substances and
Disease Registry (ATSDR) 1995; David et al.
2001]. DEHP (CAS no. 117-81-7) is used pri-
marily as a plasticizer in ﬂexible vinyl, which is
used in consumer products, ﬂooring and wall
coverings, food contact applications, and med-
ical devices (ATSDR 2002; David et al. 2001).
The potential for exposure is, to a certain
extent, a consequence of the physical and
chemical properties of each phthalate. As mol-
ecular weight increases, vapor pressure, water
solubility, and dermal uptake are reduced.
The major route of human exposure for most
phthalates is ingestion; exposure by inhala-
tion, through drinking water, and via dermal
contact tends to be limited (Clark et al. 2003).
After ingestion, phthalates are metabolized to
their corresponding hydrolytic monoesters
and may further metabolize to more
hydrophilic oxidative products. These
metabolites can be excreted unchanged or can
undergo phase II biotransformation to glu-
curonide conjugates (ATSDR 1995, 2002).
Metabolites and not the parent diesters are
likely the bioactive species (Albro 1986; Awal
et al. 2004; Bility et al. 2004; Ema et al. 2003;
Foster et al. 2000; Gray and Beamand 1984;
Gray and Gangolli 1986; Heindel and Powell
1992; Li and Kim 2003; Saillenfait et al.
2001; Stroheker et al. 2005).
Evidence of human hazard associated
with exposure to phthalates is limited, and
risk assessments have been based primarily on
results of animal studies. Administration of
some phthalates to rodents caused liver
effects, including increased weights, elevated
enzyme levels, histologic changes, and
tumors, associated with peroxisomal prolifera-
tion, that is, speciﬁcally with peroxisome pro-
liferator–activated receptor α agonism (Ward
et al. 1998), a process related to metabolism
of cholesterol and fatty acids. Due in part to
species-speciﬁc metabolic differences, the rel-
evance of these effects to humans is question-
able [International Agency for Research on
Cancer (IARC) 2000; Klaunig et al. 2003].
Nevertheless, liver effects have been used to
establish no observed adverse effect levels
(NOAELs) for risk assessment. Evidence also
exists that some phthalates and their metabo-
lites affect reproduction and development,
particularly in male rats (e.g., epididymal
malformations or absence of the epididymis,
testicular lesions, increased incidence of
hypospadias, cryptorchidism, decreased
anogenital distance, delayed preputial separa-
tion, and retention of thoracic nipples)
(Barlow et al. 2004; Barlow and Foster 2003;
Carruthers and Foster 2005; Corton and
Lapinskas 2005; Ema and Miyawaki 2001;
Fisher 2004; Foster 2005; Gray et al. 2000;
Mylchreest et al. 1998), apparently by a
process involving inhibition of androgen
biosynthesis (Parks et al. 2000).
Because DEP is used in personal care prod-
ucts, dermal toxicity is of interest. Primary der-
mal irritation with undiluted DEP has not
been reported in humans (Api 2001). DEP
was not a dermal sensitizer in healthy human
volunteers, although sensitization was reported
in some studies, mostly involving persons with
skin diseases (Api 2001). No reports exist of
oral or inhalation toxicity of DEP or of any
adverse effects in humans exposed exclusively
to DEP (ATSDR 1995). The oral reference
dose (RfD) for DEP, 800 µg/kg/day, was
derived from a NOAEL of 750 mg/kg/day
based on reduced growth rate, food consump-
tion, and increased organ weights in rats [U.S.
Environmental Protection Agency (U.S. EPA)
1993b]. No evidence of other effects in ani-
mals at lower NOAELs exists (Api 2001;
Barber et al. 2000; Gray et al. 2000).
Information on the oral toxicity of DEHP
is limited to mild abdominal pain and
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The probability of nonoccupational exposure to phthalates is high given their use in a vast range
of consumables, including personal care products (e.g., perfumes, lotions, cosmetics), paints,
industrial plastics, and certain medical devices and pharmaceuticals. Phthalates are of high interest
because of their potential for human exposure and because animal toxicity studies suggest that
some phthalates affect male reproductive development apparently via inhibition of androgen
biosynthesis. In humans, phthalates are rapidly metabolized to their monoesters, which can be fur-
ther transformed to oxidative products, conjugated, and eliminated. Phthalate metabolites have
been used as biomarkers of exposure. Using urinary phthalate metabolite concentrations allows
accurate assessments of human exposure because these concentrations represent an integrative
measure of exposure to phthalates from multiple sources and routes. However, the health signiﬁ-
cance of this exposure is unknown. To link biomarker measurements to exposure, internal dose, or
health outcome, additional information (e.g., toxicokinetics, inter- and intraindividual differences)
is needed. We present a case study using diethyl phthalate and di(2-ethylhexyl) phthalate as exam-
ples to illustrate scientific approaches and their limitations, identify data gaps, and outline
research needs for using biomonitoring data in the context of human health risk assessment, with
an emphasis on exposure and dose. Although the vast and growing literature on phthalates
research could not be covered comprehensively in this article, we made every attempt to include
the most relevant publications as of the end of 2005. Key words: biomarkers, biomonitoring,
DEHP, DEP, exposure, human, phthalate, urine. Environ Health Perspect 114:1783–1789
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Figure 1. Generic chemical structure of phthalates.
R and R´ are ethyl groups for DEP and 2-ethylhexyl
groups for DEHP.
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OR´diarrhea in two persons who ingested single
large doses (ATSDR 2002). No reports exist
of dermal or inhalation toxicity of DEHP in
adult humans, and DEHP is neither a dermal
irritant nor a sensitizer (ATSDR 2002;
Medeiros et al. 1999). DEHP does not appear
to be readily absorbed through human skin
(ATSDR 2002). Lung disorders, resembling
hyaline membrane disease, were observed in
three newborns who, as preterm infants,
received ventilation therapy involving
polyvinyl chloride tubing (ATSDR 2002).
The U.S. EPA classiﬁes DEHP as a probable
human carcinogen (B2) and, based on evi-
dence of increased liver weight in rodents,
established the RfD at 20 µg/kg/day (U.S.
EPA 1993a, 2002). IARC (2000) revised its
classiﬁcation from “probable” to “not classiﬁ-
able” after determining that the mode of
action was irrelevant to humans. Because of
the controversy regarding relevance of DEHP-
induced rodent liver cancer to humans, cancer
risk will not be discussed in this article.
In recent years the potential reproductive
and developmental effects of DEHP have
received more attention than the carcinogenic
effects. In particular, developing rats are more
sensitive to the testicular toxicity of DEHP
than are older animals [Center for the
Evaluation of Risks to Human Reproduction
(CERHR) 2005; Kavlock et al. 2002].
Exposure of rats to DEHP during the late ges-
tational period affected male reproductive
development with a NOAEL of 5–8 mg/kg
body weight/day. This NOAEL was used to
assess the potential for human reproductive
risks associated with DEHP exposure
(CERHR 2005). Similarly, a previously deter-
mined NOAEL of 3.7 mg/kg/day for testicular
effects was used by the European Union’s
Scientiﬁc Committee for Toxicity, Ecotoxicity,
and the Environment (CSTEE) as the basis for
a tolerable daily intake (TDI) of 37 µg/kg/day
(CSTEE 1998).
Biomarkers of Exposure
Phthalates are widely used in laboratory equip-
ment, and contamination is possible (Blount
et al. 2000a; Kessler et al. 2001). Sample conta-
mination problems are greatly minimized when
phthalate metabolites are measured (Blount
et al. 2000a). To select the most appropriate
biomarkers of exposure, understanding the tox-
icokinetics of individual phthalates is funda-
mental. Although differences in absorption of
phthalates exist, we address only metabolic dif-
ferences in this article.
In rats, monoethyl phthalate (MEP) is the
principal urinary metabolite of DEP; smaller
amounts of phthalic acid and DEP are also
found (Albro and Moore 1974). Metabolism
in humans is assumed to be similar (ATSDR
1995). Elimination half-lives of DEP and
MEP have not been experimentally defined
but, like DEHP and its hydrolytic metabolite
mono(2-ethylhexyl) phthalate (MEHP), are
assumed to be a few hours. These ﬁndings sug-
gest that MEP is the most sensitive and speciﬁc
biomarker of exposure to DEP.
More than 20 urinary metabolites of
DEHP have been proposed (Albro 1986). In
rodents these consist primarily of terminal oxi-
dation products. In humans the principal
DEHP metabolites are side-chain–oxidized
metabolites of MEHP (Koch et al. 2004a,
2005b). In two cancer patients receiving an
infusion of a platelet concentrate containing
DEHP, > 50% of the DEHP disappeared
from the blood in about 30 min and appeared
as DEHP derivatives in urine within 6 hr
(Peck and Albro 1982). In another study of
two volunteers who received DEHP orally, the
urinary elimination half-life of DEHP was
estimated to be 12 hr (Schmid and Schlatter
1985). The urinary excretion of DEHP
metabolites in one person after three oral
doses of D4-DEHP followed a multiphase
elimination model (Koch et al. 2004a,
2005b). For the first 4–8 hr, excretion half-
lives were approximately 2 hr for
mono(2-ethyl-5-hydroxyhexyl) phthalate
(MEHHP), mono(2-ethyl-5-oxohexyl) phtha-
late (MEOHP), and MEHP. Fourteen to
eighteen hours postadministration, half-lives
were 5 hr (MEHP) and 10 hr (MEHHP and
MEOHP) (Koch et al. 2004a). MEHHP was
the major metabolite initially; other metabo-
lites, mono(2-ethyl-5-carboxypentyl) phtha-
late and mono(2-carboxymethylpentyl)
phthalate, were more abundant starting 12 hr
after exposure (Koch et al. 2005b). The higher
urinary concentrations in humans of MEOHP
and MEHHP than of MEHP (Barr et al.
2003; Kato et al. 2004; Koch et al. 2003c,
2004b, 2005b; Silva et al. 2006a, 2006b) sug-
gest that oxidative metabolites may provide
greater analytical sensitivity than MEHP.
Furthermore, oxidative metabolites cannot be
formed as a result of sampling contamination
and may be more advantageous as biomarkers
of exposure to DEHP than MEHP. DEHP,
seldom found in blood or urine except as a
consequence of contamination, is not recom-
mended as a biomarker in studies involving
these media but may be useful in studies
involving other media (e.g., feces).
Highly specific, sensitive, accurate, and
precise analytical methods using isotope-
dilution–high-performance liquid chromatog-
raphy (HPLC) coupled with tandem mass
spectrometry for measuring parts-per-billion
levels of selected phthalate metabolites in bio-
logic matrices have been described (Blount
et al. 2000a; Calafat et al. 2004b; Kato et al.
2003a, 2003b, 2003c, 2005; Koch et al.
2003b, 2004a; Mortensen et al. 2005; Preuss
et al. 2005; Silva et al. 2003, 2004c, 2005a,
2005b; Takatori et al. 2004).
Urine (as matrix) and phthalate metabolite
concentrations (as biomarkers) represent the
most common approach to investigating
phthalate exposure in humans. Phthalate con-
centrations in blood have been reported, but
most assessed concentrations of diesters. Data
from such studies are often questionable
because of the potential for diester contamina-
tion. Consequently, methods were developed
to measure concentrations of metabolites in
serum (Kato et al. 2003b, 2004a; Silva et al.
2005b; Takatori et al. 2004), breast milk
(Calafat et al. 2004b; Mortensen et al. 2005),
saliva (Silva et al. 2005a), and human amni-
otic fluid (Silva et al. 2004b). Data from
media other than urine could also be used for
exposure assessment, but it might be more dif-
ﬁcult to collect the samples. Thus, these alter-
native media may not readily lend themselves
to large screening programs but may be useful
in speciﬁc situations.
Environmental Public Health
Uses of Biomonitoring Data
Defining human exposure to phthalates
requires measuring concentrations of parent
compounds or their metabolites in urine and
other biomatrices as well as understanding the
Calafat and McKee
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Table 1. Urinary concentrations (micrograms per gram creatinine) of MEP, MEHP, MEHHP, and MEOHP and estimated exposures (in parentheses, micrograms
per kilogram per day) to DEP and DEHP calculated using urinary concentrations from several studies of adults or the general population.
Geometric mean 95th percentile
DEP DEHP DEP DEHP
Population group MEP MEHP MEHHP MEOHP MEP MEHP MEHHP MEOHP
289 adults (Blount et al. 2000b) 345 (11.4) 3.0 (0.5) ND ND 2,610 (86.6) 15.2 (3.3) ND ND
2,536 persons 6 to > 20 years of age (Silva et al. 2004a) 163 (5.4) 3.12 (0.7) ND ND 1,950 (64.7) 18.5 (4.0) ND ND
2,772 persons 6 to > 20 years of age (CDC 2005) 167 (5.5) 3.99 (0.9) 18.8 (2.1) 12.6 (2.2) 1,860 (61.7) 32.8 (7.1) 147 (16.8) 87.5 (15.6)
85 children and adults (Koch et al. 2003c)a 165b (5.5) 12.4b (2.7) 57.2b (6.5) 41.7b (7.4) 673 (22.2) 34.7 (7.5) 143 (16.3) 106 (18.9)
ND, not determined. 
aIn their calculations of exposure, Koch et al. (2003a, 2003c) used different Fue and CE values. We recalculated the estimated exposures using the factors listed in the text, for compari-
son with other studies included in this table. bMean value.pharmacokinetics of individual phthalates. The
Centers for Disease Control and Prevention
(CDC) collects urinary metabolite data for the
general population, primarily through the
National Health and Nutrition Examination
Survey (NHANES), an ongoing national sur-
vey designed to evaluate the health and nutri-
tional status of the U.S. population. NHANES
is unique in its ability to examine public health
issues that can be addressed through physical
and laboratory examinations. NHANES
1999–2000 and 2001–2002 (CDC 2005;
Silva et al. 2004a) provided nationally repre-
sentative population-based urinary phthalate
metabolite data, based on one specimen per
participant, for selected demographic groups in
the United States. However, young (i.e.,
< 6 years of age) and older individuals (i.e.,
> 60 years of age) were not represented in the
population sampled, and no data on prenatal
exposures were collected.
Data from NHANES and other studies
conducted in the United States (Adibi et al.
2003; Blount et al. 2000b; Brock et al. 2002;
CDC 2005; Hoppin et al. 2002; Silva et al.
2004a) and abroad (Koch et al. 2003c, 2004b)
have confirmed that human exposure to
phthalates is widespread (Tables 1–3). Some
situations, not speciﬁcally addressed by large
surveys such as NHANES, may lead to phtha-
late exposures well above those found in the
general population. Examples include the use
of certain medications with enteric coatings
containing phthalates [e.g., DEP, dibutyl
phthalate (DBP)] (Hauser et al. 2004a; Koch
et al. 2005d) or related to using DEHP in
medical devices (Calafat et al. 2004a; Green
et al. 2005; Koch et al. 2005a, 2005c).
Studies of speciﬁc health effects with envi-
ronmental phthalate exposures using urinary
metabolite concentrations as exposure surro-
gates exist (Duty et al. 2003a, 2003b, 2004,
2005; Hoppin et al. 2004; Jonsson et al.
2005; Swan et al. 2005). However, these epi-
demiologic data are limited and drawing ﬁrm
conclusions has been difficult (Hauser and
Calafat 2005).
Internal Dose and Exposure
Assessment
Previous exposure assessments for phthalates
have been indirect, that is, relying on surveys
of product use, measuring phthalates in vari-
ous media, estimating human contact, and
pharmacokinetic assumptions based on animal
data. In contrast, direct methods using urinary
metabolite concentrations as biomarkers for
phthalate exposure may provide the most
accurate assessments because these concentra-
tions represent an integrative measure of expo-
sure from multiple sources and routes and can
be used to calculate phthalate exposure in the
general (Blount et al. 2000b; CDC 2005;
Koch et al. 2003c; Silva et al. 2004a) and spe-
cific populations (Adibi et al. 2003; Brock
et al. 2002; Duty et al. 2003a, 2003b, 2004;
Hoppin et al. 2002; Jonsson et al. 2005; Koch
et al. 2004b; Swan et al. 2005).
For phthalate metabolite data, two calcu-
lation methods produced similar results
(David 2000; Kohn et al. 2000). For illustra-
tive purposes, we show the method of David
(2000) as expressed by Koch et al. (2003a):
DI = (UE × CE)/(Fue × 1,000) 
× MWd/MWm, [1]
in which DI is the daily intake in milligrams
per kilogram per day; UE is the creatinine-
corrected urinary metabolite concentration in
micrograms per gram; CE is the creatinine
clearance rate, normalized for body weight, in
milligrams per kilogram per day; Fue is the
molar conversion factor that relates urinary
excretion of metabolite to diester ingested; and
MWd and MWm are the molecular weights of
diester and metabolite, respectively. For these
calculations, we set CE at 20 mg/kg/day 
for adults, 11 mg/kg/day for children, and
9.8 mg/kg/day for infants (Jacobs et al. 2001;
Tietz 1990). We set Fue at 0.69 mg/kg/day for
DEP (as MEP), 0.13 mg/kg/day for DEHP (as
MEHP), 0.23 mg/kg/day (as MEHHP), and
0.15 mg/kg/day (as MEOHP).
An Fue value for DEP has not been deter-
mined experimentally but is assumed to be
similar to the value determined for DBP
(Anderson et al. 2001). By contrast, urinary
excretion of DEHP metabolites has been stud-
ied after oral (Anderson et al. 2001; Koch et al.
2004a; Schmid and Schlatter 1985) and intra-
venous (Peck and Albro 1982) administration.
Estimating phthalate exposure from metabolite data
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Table 2. Urinary concentrations (micrograms per gram creatinine) of MEP, MEHP, MEHHP, and MEOHP and estimated exposures (in parentheses, micrograms
per kilogram per day) to DEP and DEHP calculated using urinary concentrations from several studies of children.
Geometric mean 95th percentile
DEP DEHP DEP DEHP
Population group MEP MEHP MEHHP MEOHP MEP MEHP MEHHP MEOHP
328 children 6–11 years of age (Silva et al. 2004a) 92.6 (1.7) 5.19 (0.6) ND ND 625 (11.4) 41.9 (5.0) ND ND
392 children 6–11 years of age (CDC 2005) 96.9 (1.8) 5.02 (0.6) 38.3 (2.4) 26.6 (2.6) 837 (15.3) 31.2 (3.7) 211 (13.2) 130 (12.8)
254 children 3–14 years of age (Becker et al. 2004) ND 6.2 (0.7) 40.7 (2.6) 31.2 (3.1) ND 23.7 (2.8) 170 (10.7) 119 (11.7)
36 children < 7 years of age (Koch et al. 2004b)a ND 8.7b (1.0) 55.8b (3.5) 38.3b (3.8) ND 27.5 (3.3) 113 (7.1) 75.8 (7.4)
19 children 12–18 months of age (Brock et al. 2002)c 184.1b (6.3) 4.6b (2.8) ND ND ND ND ND ND
6 premature neonates (Calafat et al. 2004a) ND 800 (85.0) 16,634 (931) 14,351 (1,256) ND 6,043 (641) 62,982 (3,523) 52,189 (4,566)
ND, not determined. 
aIn their calculations of exposure, Koch et al. (2004b) used different Fue and CE values. We recalculated the estimated exposures using the factors listed in the text, for comparison with
other studies included in this table. bMean value. cUrinary concentrations are in nanograms per milliliter (Brock et al. 2002). Estimated doses are from Clark et al. (2003) using the pub-
lished individual values for urinary creatinine (milligrams per deciliter) (Brock et al. 2002), and molar conversion factors of 0.64 (MEP) and 0.14 (MEHP).
Table 3. Urinary concentrations (micrograms per gram creatinine) of MEP, MEHP, MEHHP, and MEOHP and estimated exposures (in parentheses, micrograms
per kilogram per day) to DEP and DEHP calculated using urinary concentrations from speciﬁc populations.
Geometric mean 95th percentile
DEP DEHP DEP DEHP
Population group MEP MEHP MEHHP MEOHP MEP MEHP MEHHP MEOHP
35 African-American women (Hoppin et al. 2002) 183a (6.0) 12.3a (2.7) ND ND 611b (20.2) 77.3b (16.7) ND ND
702 non-Hispanic blacks (CDC 2005) 247 (8.2) 4.63 (1.0) 21.0 (2.4) 13.8 (2.5) 2,070 (68.7) 39.8 (8.6) 161 (18.4) 101 (18.0)
1,405 females 6–60 years of age (CDC 2005) 187 (6.2) 4.53 (1.0) 19.7 (2.2) 13.5 (2.4) 1,430 (47.4) 35.1 (7.6) 160 (18.3) 92.3 (16.5)
25 pregnant women (Adibi et al. 2003) 690a (22.9) 40.5a (8.8) ND ND 5,520b (183.1) 449b (97.4) ND ND
220 men (Duty et al. 2004)c 183.1 (6.1) 7.0 (1.5) ND ND 2,002.1 (66.4) 130.9 (28.4) ND ND
1,367 males 6–60 years of age (CDC 2005) 147 (4.9) 3.49 (0.8) 17.9 (2.0) 11.8 (2.1) 2,080 (69.0) 31.2 (6.8) 136 (15.5) 83.1 (14.8)
19 adults (Koch et al. 2004b)d ND 8.6e (1.9) 28.1e (3.2) 17.2e (3.1) ND 24.7 (5.4) 48 (5.5) 34.7 (6.2)
ND, not determined. 
aMean value. bMaximum value. cUrinary concentrations were corrected using speciﬁc gravity instead of creatinine. dIn their calculations of exposure, Koch et al. (2004b) used different
Fue and CE values. We recalculated the estimated exposures using the factors listed in the text, for comparison with other studies included in this table. eMedian value.The earliest reports of Fue for DEHP metabo-
lites came from studies that had either analyti-
cal limitations or small sample sizes (Peck and
Albro 1982; Schmid and Schlatter 1985).
Subsequently, an MEHP Fue value was deter-
mined by HPLC–mass spectrometry from a
study involving seven individuals dosed orally
with both 13C-DEHP and 13C-diisooctyl
phthalate (Anderson et al. 2001). Because the
13C-MEHP and 13C-monooctyl phthalate sig-
nals co-eluted, Fue for these species could not
be determined separately, and the MEHP
value of 0.13 is the average (Anderson et al.
2001). We used Fue for the oxidative DEHP
metabolites (MEHHP, 0.23; MEOHP, 0.15)
from a study of one adult man given three sin-
gle oral doses of D4-DEHP; the estimated Fue
for MEHP was 0.06 (Koch et al. 2005b),
about half the value used in the calculations in
this case study.
The first data on urinary phthalate
metabolite concentrations, including MEP and
MEHP, reported in a U.S. population of 289
adults from NHANES III (Blount et al.
2000b), were used to calculate exposures to the
corresponding phthalate diesters (David 2000;
Kohn et al. 2000). Subsequently, the CDC
reported U.S. nationally representative urinary
concentrations of seven phthalate metabolites
in 2,540 participants of NHANES 1999–2000
(Silva et al. 2004a) and of 10 phthalate
metabolites in 2,782 participants of NHANES
2001–2002 (CDC 2005). The frequencies of
detection of individual phthalate metabolites
were similar. However, the median concentra-
tion of MEP was almost 2-fold lower in
NHANES 1999–2000 and 2001–2002 than
in NHANES III. These differences may have
reflected reduced exposures to DEP or have
been related to differences in sample sizes. In
contrast, the MEHP concentrations remained
essentially constant, although they were 
highest in NHANES 2001–2002 (Table 1).
MEHHP and MEOHP were only measured
in NHANES 2001–2002. Their median con-
centrations were 5-fold (MEHHP) and more
than 3-fold (MEOHP) higher than the
median MEHP concentration. The NHANES
1999–2000 and 2001–2002 data, stratiﬁed by
age, gender, or ethnicity, indicated some dif-
ferences in urinary concentrations of phthalate
metabolites (CDC 2005; Silva et al. 2004a).
For MEHP, MEHHP, and MEOHP, chil-
dren exhibited higher urinary concentrations
than adults, although when accounting for
creatinine clearance, the calculated external
exposures were similar (Table 2).
Urinary concentrations of DEP and
DEHP metabolites in other smaller groups
(Adibi et al. 2003; Brock et al. 2002; Duty
et al. 2004; Hoppin et al. 2002; Koch et al.
2003c, 2004b) were largely consistent with
the NHANES 1999–2002 data (Table 3). In
general, differences between various segments
of the population were smaller than the dif-
ferences across the population, that is, from
lowest to the most highly exposed individuals.
The underlying explanation for the range of
exposures is unknown but may be related to
individual lifestyle choices. However, selec-
tion of study subjects (at least for NHANES)
did not exclude those occupationally exposed,
and specific situations may contribute to
higher exposures for some individuals (Calafat
et al. 2004a; Green et al. 2005; Hauser et al.
2004a; Koch et al. 2005a, 2005d, 2005c).
Median urinary MEP concentrations in
85 German children and adults were approxi-
mately half those in NHANES 1999–2002
(Koch et al. 2003c, 2004b). By contrast,
median urinary MEHP, MEHHP, and
MEOHP concentrations were approximately
twice those in NHANES 1999–2002, but
95th percentile values were similar (Becker
et al. 2004; Koch et al. 2003c, 2004b)
(Table 1). Whether these ﬁndings reﬂect dif-
ferences in sampling (e.g., first morning vs.
non-first morning voids, nonrepresentative
nature of the population examined in
Germany) or in exposure patterns between
the United States and Germany is unknown.
Estimates of DEP exposure resulting
from its use in personal care products, based
on conservative assumptions, were not realis-
tic (730 µg/kg/day from fragrances and
100 µg/kg/day from personal care products)
(Api 2001). With food as the largest identi-
fied contributor to exposure for most indi-
viduals, calculated median DEP exposure
ranges were 2–6 µg/kg/day for most of the
population, with somewhat higher estimates
for toddlers and lower estimates for infants
(Clark et al. 2003). For DEHP, relying heav-
ily on a previous study (Huber et al. 1996),
estimated DEHP exposure ranges within the
general population were 3–30 µg/kg/day, with
higher exposures likely in occupational settings
and the highest associated with certain med-
ical procedures (Doull et al. 1999). Estimates
from other researchers (Clark et al. 2003;
Meek and Chan 1994) also fall in this range.
For DEP a comparison of the biomarker-
based and indirect approaches indicates that,
in adults, mean estimates derived by indirect
methods (Clark et al. 2003) were about half
the mean exposures calculated from bio-
marker-based data (Table 4). Because this
indirect approach did not consider DEP
exposure from cosmetics use, these differences
are expected. The 95th percentile exposures
calculated from biomonitoring data were
above these indirect estimates but far below
unrealistic estimates of exposures from cos-
metic and personal care products (Api 2001).
One might hypothesize that exposure from
sources other than personal care products
accounts for approximately half the mean
total DEP exposure, with exposure from per-
sonal care products comprising the remain-
der. In agreement with this hypothesis,
children have lower exposures to DEP than
adults (Tables 1, 2). Three overall conclusions
emerge from this example: a) indirect meth-
ods can provide realistic estimates of exposure
only if reasonable assumptions are used;
b) use of biomonitoring data can yield precise
exposure estimates because it does not require
overly conservative assumptions; and c) it may
identify situations in which not all potential
sources of exposure were considered.
For DEHP, urinary MEHP data produced
estimates of mean exposure that were lower
than those using the indirect methods,
although the 95th percentile values were simi-
lar (Table 4). Using DEHP oxidative metabo-
lite data, the estimated DEHP exposures are
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Table 4. Estimates of the geometric mean (95th percentiles in parentheses) exposures (in micrograms per
kilogram per day) to DEP and DEHP using the geometric mean (95th percentile) urinary phthalate metabolite
concentrations compared with indirect estimates based on phthalate diester levels in various media (e.g.,
food, air, water, soil, and dust).a
DEP DEHP
Biomarker Indirect  Biomarker  Indirect 
Population group data estimate data estimate
2,772 persons 6 to > 20 years of age (CDC 2005) 5.5 (61.7) 2.5 0.9 (7.1)b 8.2
730c 2.1 (16.8)d
2.2 (15.6)e
742 adolescents 12–19 years of age (CDC 2005) 5.0 (44.1) 3.0 0.8 (5.5)b 10.0
2.2 (11.6)d
2.4 (12.6)e
392 children 6–11 years of age (CDC 2005) 1.8 (15.3) 5.7 0.6 (3.7)b 18.9
2.4 (13.2)d
2.6 (12.8)e
254 children 3–14 years of age (Becker et al. 2004) ND 0.7 (2.8)b
2.6 (10.7)d
3.1 (11.7)e
19 children 12–18 months of age (Brock et al. 2002)f 6.3g 10.6 2.8g 25.8
ND, not determined. 
aData from Clark et al. (2003). bUsing MEHP data. cData from Api (2001). dUsing MEHHP data. eUsing MEOHP data. fThe age of
the children for the indirect estimate calculations was 7 months to 4 years. gEstimated doses are from Clark et al. (2003) using
the published individual values for urinary creatinine (milligrams per deciliter) and mean urinary phthalate metabolite concen-
trations (nanograms per milliliter) (Brock et al. 2002) and molar conversion factors of 0.64 (MEP) and 0.14 (MEHP).about twice those calculated from MEHP data
(Tables 1, 2, 4). That mean DEHP exposures
within the general population, calculated from
urinary metabolite data, are approximately
4-fold lower than the indirect estimates may
be due, in part, to reliance on older measure-
ments of phthalates in various media, particu-
larly food, as the basis for indirect estimates
(Clark et al. 2003). Conservatism may also
be introduced by assumptions about absorp-
tion based on results of animal studies.
Nevertheless, this comparison suggests that,
for DEHP, all relevant sources of exposure
were taken into consideration when using the
indirect approach.
Risk Assessment
Biomonitoring data can also be used to
address the exposure component of risk
assessment. In risk assessment, exposure esti-
mates are compared with NOAELs that
for phthalates were from studies in rats.
Important and controversial issues relating to
these hazard data include choice of species,
identiﬁcation of critical end points, and rele-
vance to humans (Bosgra et al. 2005; Foster
2005). Discussing those issues in detail is
beyond the scope of this article. Rather, this
section relates results of risk assessments based
on phthalate exposures calculated from
urinary metabolite data to conclusions of
previous risk assessments.
The most reasonable indirect estimates of
mean exposure to DEP were 2–6 µg/kg/day,
depending on the ages of the groups consid-
ered and neglecting consideration of cosmet-
ics and personal care products (Clark et al.
2003). Estimates of DEP exposure in the gen-
eral population, based on biomonitoring data,
are 5.4 µg/kg/day, with a 95th percentile of
64.7 µg/kg/day (Table 4). Thus, indirect and
biomarker-based methods produced com-
parable estimates and indicated that within
the United States most individuals are
exposed to DEP levels well below the RfD
(800 µg/kg/day).
For DEHP, indirect estimates of mean
exposure were 5.8–8.2 µg/kg/day (Clark et al.
2003) and a range of 3–30 µg/kg/day (Doull
et al. 1999). From urinary metabolite data,
estimated mean exposures are in the range of
1–2 µg/kg/day, with a 95th percentile of
7–17 µg/kg/day depending on the metabolite
used (Table 4). This comparison suggests that
both indirect and biomarker-based methods
produced mean estimates below the RfD
(20 µg/kg/day) and TDI (37 µg/kg/day),
although the upper ranges of exposure
approximated the RfD. As another example,
the National Toxicology Program (NTP)
CERHR determined that the NOAEL for
reproductive effects in rats was 5–8 mg/kg/day
(CERHR 2005) and expressed concern over
the potential for reproductive risk among
infants younger than 1 year, if their exposures
were significantly higher than those of the
general population (1–30 µg/kg/day).
Biomonitoring data are unavailable for
healthy infants younger than 1 year, so this
specific question cannot be addressed from
the available data. However, for those 6 or
more years of age, biomonitoring data indi-
cate that ambient exposures to DEHP within
the United States are lower than estimates
used by the NTP-CERHR and that children’s
and adults’ exposures are comparable. Some
medical interventions may result in higher
exposures to DEHP (Calafat et al. 2004a;
Green et al. 2005; Koch et al. 2005a, 2005c).
These medical treatments entail risk–benefit
calculations that make risk assessments sub-
stantially different from those relating to
ambient exposures (U.S. Food and Drug
Administration 2001) and are beyond the
scope of this exercise. Note that for children
and adults, exposure estimates calculated from
the oxidized DEHP metabolites were approx-
imately twice those calculated from MEHP
(Tables 1, 2). However, for premature
neonates the differences were in the range of
an order of magnitude (Table 2), presumably
from differences in metabolism and/or excre-
tion in these preterm infants.
Recommendations for Future
Research
We make the following recommendations for
future research:
• Improve the understanding of human metabo-
lism and pharmacokinetics. The most rele-
vant urinary metabolites and appropriate
metabolites for other matrices that provide
the greatest analytical sensitivity must be
measured. Differences in metabolic patterns
among phthalates are important both toxi-
cologically and in exposure assessment,
especially when comparing relative expo-
sures to different phthalates because the
complex metabolism of high-molecular-
weight phthalates leads to additional meta-
bolic products (e.g., oxidative metabolites).
• Reﬁne molar conversion factors to relate exter-
nal phthalate exposure to urinary metabolite
concentrations. Based on available data, the
largest uncertainties appear in premature
neonates.
• Determine the biologic media best suited for
biomarker studies. If media other than urine
are evaluated, methodologic issues must be
considered.
• Improve the understanding of the mechanisms
of action of phthalates in humans.
• Determine whether more highly exposed
groups can be identiﬁed and, if so, identify the
sources of exposure. Potentially vulnerable
segments of the population (e.g., children,
women of reproductive age, minorities)
should be evaluated.
• Determine whether use of urinary metabolite
data as an adjunct to epidemiology studies is
possible. One speciﬁc issue relates to catego-
rizing exposure from a limited number of
urine samples (Hauser et al. 2004b; Hoppin
et al. 2002).
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